DAVID NELSON to Aged
This is a "connection" page, showing publications DAVID NELSON has written about Aged.
Connection Strength
0.160
-
Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. JAMA Netw Open. 2019 06 05; 2(6):e194765.
Score: 0.041
-
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr; 61(4):1127-35.
Score: 0.031
-
Care Models to Improve Pain and Reduce Opioids Among Patients Prescribed Long-Term Opioid Therapy: The VOICE Randomized Clinical Trial. JAMA Intern Med. 2025 Feb 01; 185(2):208-220.
Score: 0.015
-
Prevalence and cardiometabolic correlates of ketohexokinase gene variants among UK Biobank participants. PLoS One. 2021; 16(2):e0247683.
Score: 0.012
-
Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series. J Surg Oncol. 2018 Sep; 118(3):518-524.
Score: 0.010
-
Multisite Investigation of Outcomes With?Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2018 01 22; 11(2):181-191.
Score: 0.009
-
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017 10 12; 377(15):1448-1455.
Score: 0.009
-
Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016 Jan; 22(1):24-33.
Score: 0.008
-
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1594-603.
Score: 0.007
-
Frequency and stability of the fragile X premutation. Hum Mol Genet. 1994 Mar; 3(3):393-8.
Score: 0.007
-
Relationship between muscle mass and muscle strength, and the impact of comorbidities: a population-based, cross-sectional study of older adults in the United States. BMC Geriatr. 2013 Jul 16; 13:74.
Score: 0.007
-
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol. 2007 Jul; 47(1):51-9.
Score: 0.004